



Fueling the practice of  
incision-free interventional glaucoma

# Executive Summary: ViaLase is Uniquely Positioned to Unlock One of the Largest Eye Care Markets



**First & only femtosecond laser** treatment for glaucoma



**Defined regulatory path** to FDA clearance and CE Mark



**Compelling value proposition** for patients, payers and surgeons



Breakthrough technology underpinned by **specialty market & commercialization expertise**



Published clinical evidence demonstrates **excellent safety and durable IOP reduction** out to 2 years



**Attractive TAM (12M US eyes/38M EU eyes), novel business model** are catalysts for strong profitability & favorable physician economics



Strong IP with **no femtosecond laser-based glaucoma** competition



Supply chain and manufacturing **on-track for mid 2025 European launch and US IDE trial**

# Introducing ViaLase



**Tibor, Juhasz, PhD**  
Co-Founder & CEO



**Shawn O'Neil**  
President & CCO



**Hadi Srass**  
COO



**Rick Lewis, MD**  
CMO



**Brett Trauthen**  
SVP, Clinical & Regulatory



**Scott Cooper**  
CFO



**Pete England**  
VP, Global Marketing



**Ference Raksi, PhD**  
CTO



**Brendan O'Herlihy**  
VP, Global Ops



**Kristy Miller**  
Head, Human Resources

## Team


Leadership team with ~200 years of combined experience in **femtosecond laser development & commercialization**

## Mission

We're fueling the future of **incision-free interventional glaucoma** through **image-guided femtosecond laser** technology.

# The ViaLuxe™ Laser System & “FLIGHT” (Femtosecond Laser Image Guided High-precision Trabeculotomy)

- + **Ultra HD gonioscopic & OCT imaging** identify landmarks with micron accuracy
- + Femtosecond laser creates **precise apertures** in the TM
- + Customized aperture number + location, enabling 360° angle access
- + **Retreatments can be performed** as needed to maintain results






*Proprietary, incision-free femtosecond laser creates micron-accurate openings in the trabecular meshwork to enhance outflow and lower IOP.*




# ViaLase Key Points of Differentiation

- ▶ **Noninvasive:** Femtosecond laser creates a precisely defined channel without opening up the eye thus mitigating risk associated with incisional procedures
- ▶ **Superior Visualization:** HD gonioscopic & micron-accurate OCT imaging overcome traditional visualization limitations
- ▶ **Customized:** Treatment is programmable to **access all four quadrants, nasal and temporal areas alike**
- ▶ **Broad Indication:** Performed outside of cataract surgery, a common – and limiting – requirement for MIGS procedures



# First-In-Human Safety Study: 24-month Outcomes



- ▶ **Single-channel (500 x 200 $\mu$ ) treatment, no washout (N = 18)**
- ▶ **No serious adverse events** related to FLigHT treatment at any timepoint
- ▶ **34.6% mean IOP reduction** at 24 mos

At 24 Months	Mean IOP	• 88% percent of eyes achieved IOP $\leq$ 18 mmHg
	Responder Rate	• 82% percent of eyes achieved more than 20% IOP reduction (53% of patients achieved 25% or more)

Nagy Z.Z., Kranitz K., Ahmed I.I.K., De Francesco T., Mikula E. & Juhasz T., First-in-Human Safety Study of Femtosecond Laser Image Guided Trabeculotomy for Glaucoma Treatment: 24-month Outcomes, Ophthalmology Science (2023)